Image: Visual summary of Anemia Prevalence, Types, and Associated Risks by Level of Renal Function in a Cohort of 5 Million Insured Patients in the United States by Danielle K. Farrington et al (AJKD, 2022).
look more
Credit: Farrington et al, AJKD (2022)
In an analysis of ambulatory data from more than 5 million adults, hemoglobin levels were <10 g/dl in more than 20% with advanced renal disease, but less than 4% were treated with erythropoiesis-stimulating agents and had no iron testing. It was rare.
Anemia, a common complication of chronic kidney disease, is associated with adverse outcomes. Unfortunately, the use of erythropoiesis-stimulating agents (ESAs) to target normal hemoglobin levels is associated with increased cardiovascular risk. This large study of over 5 million patients sought to explain the burden and risk factors associated with anemia by estimated glomerular filtration rate (eGFR) levels. In a study published in American Journal of Kidney Disease, researchers found that severe anemia was common and strongly associated with decreased eGFR and multiple adverse outcomes. ESA use was rare. Iron studies were rarely checked, but low iron test results were common in those that were tested. emphasizes the need for increased testing of
Article title: Prevalence, types, and associated risks of anemia by level of renal function in a cohort of 5 million US insured patients
author: Danielle K. Farrington, MD, Yingying Sang, MSc, Morgan E. Grams, MD, Shoshana H. Ballew, PhD, Stephan Dunning, MBA, Nikita Stempniewicz, MSc, Josef Coresh, MD
Doi: https://doi.org/10.1053/j.ajkd.2022.07.014
journal
American Journal of Kidney Disease
Research theme
not applicable
Article publication date
September 28, 2022
Disclaimer: AAAS and EurekAlert! EurekAlert! is not responsible for the accuracy of news releases posted. Use of information by contributors or via the EurekAlert system.
